Glioblastoma Treatment Drugs Market Outlook
[333 Pages Report] The glioblastoma treatment drugs market is likely to secure a CAGR of 5.7% during the forecast period. The market is projected to be valued at US$ 723.30 million in 2022 and is expected to be valued at US$ 1,259.13 million by 2032.
The demand for glioblastoma treatment drugs is rising due to increasing geriatric populations and increasing incidence cases in recent years. The adoption of glioblastoma treatment drugs is rising with the increasing number of brain cancer tumour patients.
Moreover, some patients get beneficial clinic trials with the receiving development agents. The biomarkers seem to be more successful in personalized medicine for these patients.
This tumor is also found in the spinal cord and represents about 15.4% of all primary brain tumors, which increases the demand for glioblastoma treatment drugs. Glioblastoma is difficult to treat because of the number of different types of cells and, thus, various treatment plans combined.
In addition, drugs involved in treating glioblastoma are antineoplastic cytotoxic drugs. There is a significant development in chemotherapy drugs to treat malignant tumors, and each year there are new drugs on the market to overcome the blood-brain barrier.
Moreover, the manufacturers are playing a crucial role in developing and research several drugs for patient treatment that are likely to increase the glioblastoma treatment drugs market share during the forecast period.
Request a Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1248
Essential Drives and Constraint Factors in the Glioblastoma Treatment Drugs Market
Glioblastoma is a complicated disease, and thus the treatment for it involves various approaches combining various treatments, which is the major market driver for the glioblastoma treatment drugs market. Treating such tumours is a challenge, which forces researchers to look for diagnoses and newer chemotherapy drugs.
Changing demography, access to healthcare facilities and financial demands are some factors which are lagging in the further developments of glioblastoma. Gaining a better understanding of this disease and efficient treatment improvise, which is only possible through developments in molecular mechanisms, and clinical trials, leading to more promising and tailored therapeutic approaches.
Regional Insights:
An Eagle Eye on North America Glioblastoma Treatment Drugs Market
Among all the regions, the market is segmented into North America, Latin America, Europe, Asia Pacific and MEA. North America dominates the market by acquiring 36% of the share during the forecast period. One of the main drivers of the regional market growth is government support for the growth of the healthcare industry, as well as high awareness of uncommon conditions, easy access to high-quality medical facilities, and kind reimbursement policies.
Worldwide, there are an estimated 240,000 cases related to brain cancer, and glioblastoma is the most common and lethal disease. Every year in the U.S, there are about 18000 people diagnosed with glioblastoma disease, which has accelerated the glioblastoma treatment drugs market growth in recent years.
Request a Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1248
Examine European Glioblastoma Treatment Drugs
Europe is likely to hold the second position in the glioblastoma treatment drug market by acquiring 27% of the share during the forecast period. However, in European countries, 25000 cases are reported. Therefore there are prime incidences of this disease, which boost the market share in the region.
Moreover, various treatments are coming forward which can be used alone or in combination with radiotherapy and chemotherapy, but there are chances of reappearance. The UK is a leading country, which highlights the market due to the rising number of chemo patients in the country.
For the long-term survival of glioblastoma, there are newer combination therapies studied, and various clinical trials are to fight against this disease. These are propelling the growth of the glioblastoma treatment drugs market during the forecast period.
Key Trends in Glioblastoma Treatment Drugs
Recently, Merck & Company’s temozolomide drug was preferred and approved by the FDA for patient chemotherapy. However, bevacizumab is a treatment drug which targets VEGF-A in brain therapy patients in their early-stage trial. Bevacizumab is an anti-drug that helps to interfere in the development of blood vessels that grow a tumor. It is one of the most effective drugs approved by the FDA and is widely used to treat glioblastoma.
The U.S. FDA authorized Pfizer’s Zirabev, a biosimilar to Avastin, in June 2019 for the treatment of recurring cancers, including colorectal, NSCLC, and glioblastoma. The firm introduced its product in the United States in January 2020.
Additionally, the U.S. FDA approved Samsung’s BLA application for its SB8 bevacizumab biosimilar candidate in November 2019, increasing the likelihood that products may be released in the upcoming years.
The U.S. FDA granted fast-track designation to Denovo Biopharma’s DB102 (enzastaurin) in July 2020 for the treatment of people who have just received a glioblastoma diagnosis.
Competitive Landscape:
How are Key Players Advancing the Glioblastoma Treatment Drugs Market?
The key players are the main drivers of the market, who have played a crucial role in uplifting the market size in recent years. These players are using several marketing tactics to boost the market by acquiring the lion’s share during the forecast period.
Some of the marketing methodologies adopted by them are mergers, product launches, partnerships, collaborations and others.
Recent Developments in the Glioblastoma Treatment Drugs Market
Some of the developments in glioblastoma are currently under research by prominent manufacturers, as follows:
- Gene therapy
- Theraphy on specific tumor – Afatinib, Aldoxorubicin, CBL0137, Val-083
- Kinase inhibitor
- Immunotherapy vaccines – Prophage, DCVax-L, Rindopepimut, Gliovac
- Glioma stem cell targeting
- Virus
- MiRNA targeting
- Others
These are the under-processing development therapies which are likely to be developed by experts and R&D teams in the coming years. The manufacturers are popping out year-on-year with a unique & advanced therapy for glioblastoma treatment.
- In 2019, Merck company acquired Peloton Therapeutics, which is a bio-therapeutic clinical-stage company. The acquisition helps to treat brain cancer with the strongly developed small molecule to treat hypoxia-inducible factor-2α (HIF-2α). Therefore, these help to treat cancer treatment with more strengthening and are boosting the market size of glioblastoma treatment drugs all around the globe.
- Lineage Cell Therapeutics and Immunomic Therapeutics came into a licensing deal in April 2021 for the creation of the allogeneic VAC cancer immunotherapy platform, which is used to treat glioblastoma multiform. According to the deal, Lineage received a USD 2 million upfront payment, as well as USD 67 million in commercial milestone payments.
Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-1248
Key Players in the Glioblastoma Treatment Drugs Market are
- F. Hoffmann-La Roche AG,
- Merck & Co., Inc.,
- Sandoz
- Arbor Pharms LLC.
- Emcure Pharmaceuticals Ltd.
- Bristol-Myers Squibb Company
- Sigma-Tau Pharmaceuticals, Inc.
Report Scope
Growth Rate
- CAGR of 5.7% from 2022 to 2032
Base Year for Estimation
- 2021
Historical Data
- 2016-2021
Forecast Period
- 2022-2032
Quantitative Units
- Revenue in US$ million and CAGR from 2022-2032
Report Coverage
- Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
- Drug Class
- Distribution Channel
- Region
Regions Covered - North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Key Countries Profiled - U.S
- Canada
- Brazil
- Argentina
- Germany
- U.K
- France
- Spain
- Italy
- Nordics
- BENELUX
- Australia & New Zealand
- China
- India
- ASEAN
- GCC
- South Africa
Key Companies Profiled
- F. Hoffmann-La Roche AG,
- Merck & Co., Inc.,
- Sandoz
- Arbor Pharms LLC.
- Emcure Pharmaceuticals Ltd.
- Bristol-Myers Squibb Company
- Sigma-Tau Pharmaceuticals, Inc.
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs